# Modulation of SIRT1/PPARγ pathways and tight junction proteins by nicotinamide riboside under chronic variable stress

**Authors:** Abdullah Celik, Nurhan Sahin, Cemal Orhan, Besir Er, Fusun Erten, Busra Ozmen, Mehmet Tuzcu, Ibrahim Hanifi Ozercan, Kazim Sahin

PMC · DOI: 10.1007/s13105-026-01153-7 · 2026-01-22

## TL;DR

This study shows that nicotinamide riboside (NR) can help reduce stress-related health issues like liver damage and intestinal problems by improving metabolism and gut barrier function.

## Contribution

The study reveals NR's novel effects on liver metabolism, intestinal barrier integrity, and SIRT1/PPARγ pathways under chronic stress.

## Key findings

- NR supplementation corrected stress-induced biochemical imbalances and upregulated hepatic markers like PPARγ and SIRT1.
- NR strengthened intestinal barrier integrity by promoting tight and adherens junction proteins.
- High-dose NR reduced liver fibrosis and improved glucose metabolism in stressed rats.

## Abstract

Chronic stress disrupts homeostasis, leading to major health problems such as liver damage, intestinal barrier dysfunction, and impaired glucose metabolism. Although current treatments, including anxiolytics, sedatives, antidepressants, and beta blockers, are effective, their adverse effects emphasize the need for safer alternatives. Nicotinamide riboside (NR), a precursor of nicotinamide adenine dinucleotide (NAD+), plays a central role in energy metabolism and oxidative stress regulation; elevated NAD + levels have been associated with reduced risk of chronic diseases such as obesity and type 2 diabetes. However, the effects of NR on liver metabolism, intestinal barrier integrity, and related protein pathways remain unclear. This study investigated the effects of NR supplementation in rats exposed to chronic variable stress (CVS). Fifty-six male Sprague Dawley rats were divided into normal and CVS groups and treated in a 2 × 4 factorial design with 0, 150, 300, or 600 mg/kg NR. Under CVS conditions, serum glucose, corticosterone, ACTH, and insulin levels increased, whereas NAD+, NADPH, nicotinamide (NAM), and nicotinic acid (NA) decreased significantly (p < 0.001). NR supplementation effectively corrected these biochemical imbalances and upregulated hepatic markers, including PPARγ, SIRT1, GLUT2, IRS1, and FASN (p < 0.001). Furthermore, the increased expression of key transport proteins such as PepT1, LAT2, EAAT3, FABP2, and FATP4 contributed to maintaining intestinal barrier integrity and improving gut health. NR also promoted the recovery of tight and adherens junction proteins. Notably, high-dose NR (600 mg/kg) markedly alleviated liver fibrosis, improved glucose metabolism, and strengthened intestinal barrier function, demonstrating its therapeutic potential as an alternative strategy against stress-induced metabolic disorders.

• NR mitigated chronic stress-induced liver, intestinal, and glucose dysregulation.

• NR improved glycemia and NAD⁺-related biomarkers under stress.

• NR reduced hepatic fibrosis markers.

• NR strengthened TJ/AJ proteins, supporting intestinal barrier integrity.

• Findings support NR’s therapeutic potential in stress-related metabolism.

The online version contains supplementary material available at 10.1007/s13105-026-01153-7.

## Linked entities

- **Genes:** PPARG (peroxisome proliferator activated receptor gamma) [NCBI Gene 5468], SIRT1 (sirtuin 1) [NCBI Gene 23411], SLC2A2 (solute carrier family 2 member 2) [NCBI Gene 6514], IRS1 (insulin receptor substrate 1) [NCBI Gene 3667], FASN (fatty acid synthase) [NCBI Gene 2194], SLC15A1 (solute carrier family 15 member 1) [NCBI Gene 6564], LAT2 (linker for activation of T cells family member 2) [NCBI Gene 7462], SLC1A1 (solute carrier family 1 member 1) [NCBI Gene 6505], FABP2 (fatty acid binding protein 2) [NCBI Gene 2169], SLC27A4 (solute carrier family 27 member 4) [NCBI Gene 10999]
- **Chemicals:** nicotinamide riboside (PubChem CID 439924), NAD+ (PubChem CID 5892), NADPH (PubChem CID 5884), nicotinamide (PubChem CID 936), nicotinic acid (PubChem CID 938)
- **Diseases:** obesity (MONDO:0011122), type 2 diabetes (MONDO:0005148)

## Full-text entities

- **Genes:** Muc2 (mucin 2, oligomeric mucus/gel-forming) [NCBI Gene 24572] {aka AABR07006030.1, HH-Muc, MLP}, Fasn (fatty acid synthase) [NCBI Gene 50671], Mtor (mechanistic target of rapamycin kinase) [NCBI Gene 56718] {aka Frap1, RAFT1}, Sirt1 (sirtuin 1) [NCBI Gene 309757] {aka Sir2}, Ocln (occludin) [NCBI Gene 83497], Slc27a4 (solute carrier family 27 member 4) [NCBI Gene 311839] {aka Fatp4}, Sirt1 (sirtuin 1) [NCBI Gene 93759] {aka SIR2L1, Sir2, Sir2a, Sir2alpha}, Cldn1 (claudin 1) [NCBI Gene 65129], Cldn4 (claudin 4) [NCBI Gene 304407], Lat2 (linker for activation of T cells family, member 2) [NCBI Gene 317676] {aka Ntal, Wbscr5}, Actb (actin, beta) [NCBI Gene 81822] {aka Actx}, Tjp1 (tight junction protein 1) [NCBI Gene 292994] {aka ZO-1}, Slc2a2 (solute carrier family 2 member 2) [NCBI Gene 25351] {aka GTT2, Glut2}, Slc1a1 (solute carrier family 1 member 1) [NCBI Gene 25550] {aka Eaac1, Eaat3, REAAC1}, Irs1 (insulin receptor substrate 1) [NCBI Gene 25467] {aka IRS1IRM}, Slc15a1 (solute carrier family 15 member 1) [NCBI Gene 117261] {aka Pept1}, Cat (catalase) [NCBI Gene 24248] {aka CS1, Cas1, Cat01, Catl, Cs-1}, Mfsd4b2 (major facilitator superfamily domain containing 4B2) [NCBI Gene 309810] {aka RGD1304770}, Fabp2 (fatty acid binding protein 2) [NCBI Gene 25598] {aka FABP}, nr (nervous) [NCBI Gene 18170], Slc7a8 (solute carrier family 7 member 8) [NCBI Gene 84551] {aka Lat2, Lat4}, Pparg (peroxisome proliferator-activated receptor gamma) [NCBI Gene 25664] {aka PPARgamma2}, Srebf1 (sterol regulatory element binding transcription factor 1) [NCBI Gene 78968] {aka ADD-1, ADD1, SREBP-1, SREBP-1c, Srebp1}, SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}, Slc5a1 (solute carrier family 5 member 1) [NCBI Gene 25552] {aka SGLT1, SGLT1a}, Got2 (glutamic-oxaloacetic transaminase 2) [NCBI Gene 25721] {aka ASPATA, mAAT}
- **Diseases:** neurodegeneration (MESH:D019636), CVS (MESH:D013313), neuropsychiatric conditions (MESH:D001523), systemic (MESH:D015619), hyperglycemia (MESH:D006943), liver, intestinal, and glucose dysregulation (MESH:D017093), mucosal injury (MESH:D052016), mitochondrial dysfunction (MESH:D028361), obese (MESH:D009765), peripheral neuropathy (MESH:D010523), inflammatory bowel disease (MESH:D015212), atrophy (MESH:D001284), toxicity (MESH:D064420), hepatic fibrosis (MESH:D008103), cancer (MESH:D009369), neuropathy (MESH:D009422), lipid malabsorption (MESH:D011017), type 2 diabetes (MESH:D003924), dysbiosis (MESH:D064806), hepatic (MESH:D056486), hepatic and intestinal dysfunction (MESH:D007410), non-alcoholic fatty liver disease (MESH:D065626), cardiometabolic disease (MESH:D024821), glucose (MESH:D018149), gastrointestinal alterations (MESH:D005767), Chronic (MESH:D002908), insulin resistance (MESH:D007333), metabolic abnormalities (MESH:D008659), weight gain (MESH:D015430), inflammation (MESH:D007249), renal impairment (MESH:D007674), dysfunction (MESH:D006331), anxiety (MESH:D001007), hepatic steatosis (MESH:D005234), impaired glucose metabolism (MESH:D044882), hepatic and intestinal injury (MESH:D000090124)
- **Chemicals:** glucose (MESH:D005947), NAM (MESH:D009536), amino acid (MESH:D000596), lipid (MESH:D008055), fatty acid (MESH:D005227), formaldehyde (MESH:D005557), N (MESH:D009584), SDS (MESH:D012967), peptide (MESH:D010455), xylene (MESH:D014992), CVS (-), creatinine (MESH:D003404), urea (MESH:D014508), NR (MESH:C018613), Eosin (MESH:D004801), Laemmli buffer (MESH:C088816), NA (MESH:D009525), H&amp;E (MESH:D006371), Corticosterone (MESH:D003345), Triglyceride (MESH:D014280), alcohol (MESH:D000438), water (MESH:D014867), NADPH (MESH:D009249), oligopeptides (MESH:D009842), paraffin (MESH:D010232), NAD + (MESH:D009243), glycemia (MESH:D001786), Hematoxylin (MESH:D006416), chloride (MESH:D002712)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606]

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12823639/full.md

---
Source: https://tomesphere.com/paper/PMC12823639